Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 27, 2011 Brian Orelli	Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections.
The Motley Fool January 6, 2012 David Williamson	Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares.
The Motley Fool April 26, 2011 Brian Orelli	We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.
The Motley Fool June 24, 2011 Brian Orelli	Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why?
The Motley Fool August 27, 2008 Brian Orelli	Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note.
The Motley Fool December 7, 2007 Brian Lawler	Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy.
The Motley Fool June 20, 2011 Brian Orelli	Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next.
The Motley Fool February 11, 2009 Brian Orelli	The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool December 11, 2008 Brian Orelli	A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone.
The Motley Fool May 29, 2007 Brian Lawler	The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool December 9, 2008 Brian Orelli	Presents or Coal From the FDA? Let's take a look at a few companies expecting FDA decisions this month and see whether they're more likely to get a present or a lump of coal in their marketing-application stockings.
The Motley Fool November 27, 2009 Brian Orelli	A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence.
The Motley Fool May 5, 2008 Brian Lawler	Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week.
The Motley Fool June 11, 2008 Brian Lawler	Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals?
The Motley Fool November 2, 2007 Brian Lawler	A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note.
The Motley Fool November 14, 2008 Brian Orelli	Gravy or Turkey From the FDA? Johnson & Johnson, Genzyme, and AstraZeneca should be made aware of their FDA fate over the next few weeks.
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool November 10, 2005 W.D. Crotty	Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%.
The Motley Fool April 1, 2008 Brian Lawler	A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics.
The Motley Fool November 21, 2008 Brian Orelli	Manufacturing Pain Johnson & Johnson has plenty of it.
The Motley Fool February 22, 2010 Brian Orelli	So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits.
The Motley Fool December 31, 2009 Brian Orelli	The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims.
The Motley Fool November 13, 2007 Brian Orelli	Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note.
The Motley Fool May 29, 2009 Brian Orelli	Delayed, Reason Unknown As long as Bayer and Johnson & Johnson can answer the FDA's questions relatively quickly, it shouldn't affect the companies too much.
The Motley Fool May 19, 2009 Brian Orelli	Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies.
The Motley Fool May 31, 2011 Brian Orelli	Pay Attention, Biotech Investors Competitors and partners can't be ignored.
The Motley Fool December 14, 2009 Brian Orelli	Finally Released From an Extended Review The FDA finally approves extended-release Zyprexa.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool November 28, 2008 Brian Orelli	The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value.
The Motley Fool March 30, 2005 David Nierengarten	Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives?
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool December 1, 2010 Brian Orelli	We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell.
The Motley Fool May 2, 2007 Brian Lawler	Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool July 24, 2007 Brian Lawler	Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it.
The Motley Fool March 3, 2009 Robert Steyer	Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool March 17, 2009 Brian Orelli	Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.
The Motley Fool August 9, 2011 Brian Orelli	Some Potential Good News in Biotech The FDA should approve Gilead's Btripla.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool February 7, 2005 Brian Gorman	Alkermes Is Coming of Age The drug delivery company may soon have its own drug on the market.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool November 10, 2009 Brian Orelli	3 Companies Looking for Gratitude Early These three small drug companies all have PDUFA dates in the next week: Cadence Pharmaceuticals... NeurogesX... Genzyme...
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
Chemistry World August 9, 2012	Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.